A phase IIb trial of remogliflozin etabonate in patients with non-alcoholic steatohepatitis.
Phase of Trial: Phase II
Latest Information Update: 31 Mar 2016
Price : $35 *
At a glance
- Drugs Remogliflozin etabonate (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors Avolynt; BHV Pharma; Islet Sciences
- 23 Apr 2015 According to a company media release, Islet Sciences plans to initiate this study in 2015.
- 15 Oct 2014 New trial record